MERRIMACK PHARMACEUTICALS IN's ticker is MACK and the CUSIP is 590328209. A total of 70 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $118,000 | – | 8,128 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| 22NW, LP | 1,092,263 | $7,591,000 | 5.28% |
| Western Standard LLC | 425,359 | $2,956,000 | 2.62% |
| Newtyn Management, LLC | 1,144,583 | $7,955,000 | 1.50% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 216,118 | $1,502,000 | 0.64% |
| Yakira Capital Management, Inc. | 66,934 | $465,000 | 0.13% |
| Cannell & Co. | 49,960 | $347,000 | 0.01% |
| OXFORD ASSET MANAGEMENT LLP | 69,630 | $484,000 | 0.01% |
| Valeo Financial Advisors, LLC | 9,000 | $63,000 | 0.01% |
| Connor, Clark & Lunn Investment Management Ltd. | 161,774 | $1,124,000 | 0.01% |
| WEBSTER BANK, N. A. | 3,055 | $21,000 | 0.00% |